SEC Form 4 · accession 0000899243-18-002333
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric D. Shaff
Officer — See Remarks
Period of report
Jan 26, 2018
Accepted (ET)
Jan 30, 2018 · 9:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1 | Jan 26, 2018 | M | 8,000 | — | A | 8,000 | D | |
| COMMON STOCK | Jan 26, 2018 | S | 2,780 | $11.02 | D | 5,220 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RESTRICTED STOCK UNITSF1,F2 | — | Jan 26, 2018 | M | 8,000 | D | — | — | COMMON STOCK | 8,000 | 32,000 | D |
| STOCK OPTION (RIGHT TO BUY)F3 | $10.42 | Jan 30, 2018 | A | 120,000 | D | — | Jan 29, 2028 | COMMON STOCK | 120,000 | 120,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- F2These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020.
- F3The Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Remarks
Chief Financial Officer and EVP